Authors


Allison Kalloo

Latest:

5 Ways DCTs Can Positively Impact Trial Diversity

COVID-19 forces life sciences industry to make long overdue changes.


Sowmyanarayan Srinivasan, Tanvi Vedhera, Garima Prashad, and Vishakha Sharma

Latest:

Leveraging Technology for Efficient Trial Design

Teams must work together with technology solutions and optimize integration to unlock their full potential.


Mariel Fabro

Latest:

Advancing COPD Research: Harnessing Wearable Sensors and Remote Monitoring for Improved Insights

Wearable sensors and remote monitoring technology can help HCPs monitor and manage COPD more effectively.


Yannis Jemiai

Latest:

Employing the Power of Bayesian Methods to Expedite Learning

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.



Simon Jones

Latest:

Clinical Trials Supply Chain: How to Respond to Recent Transformations

Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.


Kenton Zavitz, PhD

Latest:

The Importance of Using Cognition as an Endpoint in Clinical Trials

How cognitive evaluations can aid in meeting the growing demand for more comprehensive safety profiles.


Archana Sah

Latest:

Optimizing Technology Implementation to Improve Diversity in Clinical Research

Three key considerations for deploying technology to help increase diversity in trials.


Andrew Hsu

Latest:

Towards Data-Driven Clinical Trial Planning and Strategy

Optimizing feasibility through increased data collection.


Kent Buhler

Latest:

How to Address—and Overcome—Operational Challenges in Master Protocol Studies

Trials that address multiple questions simultaneously using a master protocol can be operationally complicated. These complexities can be managed, even in studies used to support a marketing application.


Chris Crabtree

Latest:

What Patients Expect from Clinical Trials in the COVID-19 Era

Key takeaways from a survey of 250 oncology patients measuring COVID-19’s impact on patient willingness to participate in clinical trials.


Krystle Karoscik

Latest:

Immunomodulators and Cancer Research

Distinguishing CAR-T and CPI approaches and the clinical trial challenges and complexities associated with each.


Saama

Latest:

Three Ways to Leverage AI in Clinical Trials - Right Now

This eBook will discuss three key ways that researchers can implement AI to address data challenges, improve patient safety and outcomes, and accelerate processes.


Maria I. Florez

Latest:

Improving Diversity in Clinical Trial Volunteer Participation by Addressing Racial and Ethnic Representation Among the Clinical Research Workforce

2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.


Owen Corbin

Latest:

Confidentiality in DCT: How to Utilize Third-Party Home Health Providers

Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.


Jonathan Jackson

Latest:

Importance of Diversity in Parkinson’s Research

Eliminating barriers to engage underrepresented populations.


C.K. Wang, MD

Latest:

Real-World Data Offers Significant Opportunities for Developing New Therapies for Hematologic Cancers

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.


Roger Sands

Latest:

WiFi Automation Keeps Decentralized Clinical Trials Running

Reliable internet connection an integral part of movement to DCTs.


Inger Ødum Nielsen, Vanessa de Langsdorff, and John April

Latest:

How Medical Writing and Regulatory Affairs Professionals Can Embrace and Deploy Generative AI at Scale

Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.


WCG Clinical

Latest:

WCG Randomized 1,600 Participants for RSV Vaccine Trial

A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.


Jian Wang, PhD

Latest:

Integration of Point-of-Care Devices in Clinical Trials

A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.


Christine Senn

Latest:

From Isolation to Integration: Improving Site-Sponsor Collaboration in Clinical Trial Startup

It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.


Megan Hooton

Latest:

Building Relationships Key for Smaller Sponsors

Strong collaboration critical as trial development advances.


Afrah Shafquat

Latest:

Accelerating Breakthroughs with Synthetic Clinical Trial Data

The emergence of AI-powered simulants in improving study efficiency.



Vivek Vaishya

Latest:

Future of Clinical Trial Documentation Management: eTMF Integrated with Blockchain

eTMF-blockchain technology offers a myriad of application benefits to data quality and integrity while ensuring compliance to ethical standards.


Teonna Woolford

Latest:

Making Clinical Research More Equitable Makes for More Effective Medications

Decentralized trials provide promise for lowering barriers in participation, but industry must continue to be proactive in patient centricity.


Nick Collins

Latest:

eSource Interoperability Between EHR and EDC

Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.


Jade Dennis

Latest:

Towards Data-Driven Clinical Trial Planning and Strategy

Optimizing feasibility through increased data collection.


Karoline Hahn

Latest:

Somatic Cell Therapy—Navigating the Regulatory Landscape

The diversified sources of the somatic cells call for additional oversight to prevent the introduction, transmission, and spread of communicable disease.

© 2025 MJH Life Sciences

All rights reserved.